Impact of HTA Therapeutic Reviews on

Real World Clinical Practice: The MS

Society of Canada’s Perspective

Dr. Karen Lee, Vice-President Research

www.medicinenet.com

• Reduce relapse disability• Reduce relapse rate

• Reduce or stop progression• Remyelination• Neuroprotection

10 therapies approved in Canada with more in the pipeline

0 therapies available

Stable

A B C

MS Population Variability

DMT DMT DMT

Progressive MS

Stable Progressive MS

“The unpredictable aspect is paramount since no 2 days are the same and no 2 hours at the same”

“ I believe I would be in a wheelchair without this medicine so I continue giving myself an injection once a day until a cure is found”

“ I would be interested in trying new drugs if they have minimal side effects and were taken orally rather than injection base.”

Views on the Therapeutic Review

• Assumes all people living with MS are alike, does not take into account the variability in the MS population

• Restrictive nature of recommendations, does not allow for choice and personalized medicine approach

• Focused on cost effectiveness versus the person living with MS